Exclusive negotiations for a partnership between Pierre Fabr

Laboratoires Pierre Fabre (France) and Merz Pharmaceuticals (Germany) today announced exclusive negotiations on a partnership project in the field of cosmetic dermatology. Initially, Merz plans to acquire the range of injectable hyaluronic acid-based brand Glytone ® used to fill wrinkles, as well as several Dermocosmetics products.

If the proposed transaction will proceed, Merz will own the worldwide rights to the injectable hyaluronic acid-based and rights outside the U.S. for other brand products Glytone ®. This transaction would reinforce the strategy of Merz in the field of cosmetic medicine, a multi-billion strong growth market.

"This project with Pierre Fabre would reinforce our global position in cosmetic dermatology," said Hans-Jörg Bergler, Director of Corporate Development group Merz. "Following the acquisition of BioForm in 2010, this new project demonstrates our commitment to strengthening our portfolio tirelessly with highly innovative products. We intend to work closely with Pierre Fabre to the integration of Glytone ® fillers in our global portfolio of products, and identify possible opportunities with them capitalizing on our complementary expertise in cosmetic dermatology. "